Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Hematology

Is There a Cure for Glanzmann Thrombasthenia? Explained

At a Glance

Yes, Glanzmann Thrombasthenia can be permanently cured with a stem cell transplant (bone marrow transplant). However, due to severe risks like Graft-versus-Host Disease, this cure is rarely used. Most patients manage the condition lifelong with medications to prevent and stop severe bleeding.

In this answer

3 sections

01

The Only Known Cure: Stem Cell Transplantation

02

Why a Cure is Not Automatically Offered

03

What Lifelong Management Looks Like

Yes, there is a permanent cure for Glanzmann Thrombasthenia, but it is not the standard treatment for most people. Because the condition is caused by a genetic defect affecting your blood platelets, the only way to permanently cure it is through a Hematopoietic Stem Cell Transplant (HSCT)—commonly known as a bone marrow transplant [1][2]. For the vast majority of people, however, Glanzmann Thrombasthenia is a lifelong condition managed with treatments that prevent and stop bleeding, rather than curing the disease [3][4].

The Only Known Cure: Stem Cell Transplantation

A Hematopoietic Stem Cell Transplant (HSCT) involves replacing your defective bone marrow with healthy stem cells from a matching donor [1][5]. Because bone marrow is the factory that produces your blood cells, introducing healthy donor stem cells allows your body to start producing normal, properly functioning platelets [1][2].

Clinical evidence shows that when the donor cells successfully take hold (engraftment), platelet function can normalize. This can entirely correct the bleeding disorder, allowing patients to live symptom-free without the need for future treatments [1][2][5].

Why a Cure is Not Automatically Offered

If a cure exists, it is natural to wonder why it is not the first line of treatment. The reality is that an HSCT is an intense, high-risk medical procedure [6][7].

The decision to pursue a transplant requires carefully weighing the potential for a cure against the severe risks associated with the procedure [6][7]. One major risk is Graft-versus-Host Disease (GvHD), a potentially serious complication where the new donor immune cells mistakenly attack your body’s own tissues [2].

Because of these inherent dangers, stem cell transplants for Glanzmann Thrombasthenia are generally reserved for:

  • Patients with severe, life-threatening bleeding episodes that cannot be controlled [7][8].
  • Individuals who have developed resistance to standard treatments and require frequent hospitalizations [7][5].
  • Cases where the condition causes a profoundly poor quality of life despite maximal medical support [8][7].

What Lifelong Management Looks Like

For most individuals with Glanzmann Thrombasthenia, care focuses on lifelong symptom management. This approach centers on stopping acute bleeding episodes, preparing for procedures like surgery or dental work, and avoiding triggers that worsen bleeding [9][10].

Everyday Safety and Medications to Avoid

Living with Glanzmann Thrombasthenia means being vigilant about everyday medications. It is strictly recommended to avoid over-the-counter pain relievers that interfere with platelet function, such as aspirin and NSAIDs (like ibuprofen, Motrin, and naproxen) [11][12][13]. Taking these medications compounds your existing platelet defect and significantly increases the risk of severe bleeding [11][14]. For pain relief, acetaminophen is generally considered a safer alternative [15][4]. Patients are also widely advised to wear a medical alert bracelet and establish an emergency bleed plan with their hematologist.

Standard Medical Treatments

When treatment is needed, standard management strategies include:

  • Recombinant activated factor VII (rFVIIa) (e.g., NovoSeven): This is a medication given intravenously that helps your blood clot by bypassing the defective platelets. It is considered highly safe and effective for both surgical and non-surgical bleeding [10][9][16].
  • Platelet Transfusions: Receiving donor platelets can stop severe bleeding [17][18]. However, doctors try to limit transfusions because repeated exposure to donor blood can cause alloimmunization—a condition where your immune system develops antibodies against donor platelets, making future transfusions less effective [17][18][19]. When this happens, rFVIIa becomes the essential preferred treatment [19][20].
  • Antifibrinolytics: Medications that slow the breakdown of blood clots (such as tranexamic acid or Amicar) are frequently used to treat mucosal bleeding, including frequent nosebleeds, heavy periods, or gum bleeding [21][22][3].
  • Hormonal Therapies: For women experiencing severe heavy menstrual bleeding, hormonal treatments like birth control pills or specific intrauterine devices (IUDs) are commonly used alongside antifibrinolytics to manage symptoms [3][23].
  • Iron Supplements: Because chronic bleeding can lead to low iron levels, many patients require monitoring and treatment for iron deficiency anemia [24][25][26].

Common questions in this guide

Do Glanzmann Thrombasthenia Carriers Have Bleeding Symptoms?Does Glanzmann Thrombasthenia Shorten Life Expectancy?Does Type 1 Glanzmann Thrombasthenia Mean Worse Bleeding?How Does Glanzmann Thrombasthenia Differ From HemophiliaHow Rare is Glanzmann Thrombasthenia? Prevalence & FactsHow to Stop Severe Nosebleeds with GTWill I Pass Glanzmann Thrombasthenia to My Baby?How to Manage Heavy Periods with Glanzmann ThrombastheniaCan You Have a Baby With Glanzmann Thrombasthenia?What Sports Are Safe for Glanzmann Thrombasthenia?What to Include in a GT Emergency LetterWhy Avoid NSAIDs With Glanzmann Thrombasthenia?Why Avoid Platelet Transfusions in GT?Why Do Blood Tests Miss Glanzmann Thrombasthenia?How to Manage Dental Surgery with Glanzmann Thrombasthenia
Is there a permanent cure for Glanzmann Thrombasthenia?
Yes, a hematopoietic stem cell transplant (bone marrow transplant) is the only known permanent cure. It replaces defective bone marrow with healthy donor stem cells, allowing your body to produce normal platelets.
Why isn't a stem cell transplant the standard treatment for everyone?
Stem cell transplants carry severe risks, including Graft-versus-Host Disease, where donor immune cells attack your body. Because of these dangers, transplants are typically reserved for patients with life-threatening bleeding that cannot be managed with standard treatments.
What medications should I avoid if I have Glanzmann Thrombasthenia?
You must strictly avoid over-the-counter pain relievers that interfere with platelet function, such as aspirin and NSAIDs like ibuprofen or naproxen. These medications worsen your existing platelet defect and significantly increase your risk of severe bleeding.
What is alloimmunization in Glanzmann Thrombasthenia?
Alloimmunization happens when your immune system develops antibodies against donor platelets after repeated transfusions. This makes future platelet transfusions less effective, which is why doctors try to limit them and use alternative medications when possible.
How are bleeding episodes typically managed?
Bleeding is typically managed with recombinant activated factor VII (rFVIIa) or platelet transfusions. Antifibrinolytic medications and hormonal therapies are also commonly used to manage frequent nosebleeds, gum bleeding, or heavy periods.

Questions for Your Doctor

6 questions

  • •What is my current bleeding risk profile, and do you consider my case mild, moderate, or severe?
  • •How will we monitor for the development of platelet antibodies (alloimmunization) if I need transfusions?
  • •What thresholds or specific bleeding patterns would make us consider more aggressive interventions like a stem cell transplant?
  • •What is our emergency plan if I have a severe bleed that doesn't stop with standard at-home or clinic measures?
  • •How can I safely manage pain, and are there specific over-the-counter pain relievers I should completely avoid?
  • •What are my best options for safely managing heavy menstrual bleeding?

Questions for You

4 questions

  • •How significantly does bleeding or the fear of bleeding impact my daily quality of life and activities?
  • •Have I noticed my usual treatments becoming less effective when I have a bleeding episode?
  • •Am I comfortable with the current emergency plan I have in place for sudden, severe bleeding?
  • •Do I have all my emergency medical information, such as a medical alert bracelet or wallet card, readily available?

References

References (26)
  1. 1

    Excellent Outcome Following Sibling Peripheral Blood Hematopoietic Stem Cell Transplantation for Glanzmann Thrombasthenia: A Case Report.

    Li JH, Sun SW, Ai Y, et al.

    Frontiers in pediatrics 2021; (9()):776927 doi:10.3389/fped.2021.776927.

    PMID: 35198519
  2. 2

    Stem Cell Transplant in Severe Glanzmann Thrombasthenia in an Adult Patient.

    Ramzi M, Dehghani M, Haghighat S, Nejad HH

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2016; (14(6)):688-690 doi:10.6002/ect.2014.0165.

    PMID: 26134714
  3. 3

    How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults.

    Grainger JD, Thachil J, Will AM

    British journal of haematology 2018; (182(5)):621-632 doi:10.1111/bjh.15409.

    PMID: 30117143
  4. 4

    The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia.

    Di Minno G, Zotz RB, d'Oiron R, et al.

    Haematologica 2015; (100(8)):1031-7 doi:10.3324/haematol.2014.121475.

    PMID: 26001793
  5. 5

    Successful Use of Hematopoietic Stem Cell Transplantation for 2 Pediatric Cases of Glanzmann Thrombasthenia and Review of the Literature.

    Friend BD, Roach GD, Kempert PH, Moore TB

    Journal of pediatric hematology/oncology 2020; (42(6)):e521-e526 doi:10.1097/MPH.0000000000001646.

    PMID: 31693514
  6. 6

    Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease.

    Spilleboudt C, De Wilde V, Lewalle P, et al.

    Frontiers in immunology 2020; (11()):579151 doi:10.3389/fimmu.2020.579151.

    PMID: 33537027
  7. 7

    Mixed Chimerism and Clinical Outcome of Hematopoietic Stem Cell Transplantation in Glanzmann Thrombasthenia: Experience on 2 Siblings and Literature Review.

    Al-Antary ET, Chitlur M, Gadgeel M, Savaşan S

    Journal of pediatric hematology/oncology 2025; (47(8)):429-435 doi:10.1097/MPH.0000000000003121.

    PMID: 40928240
  8. 8

    Stem Cell Transplantation in Glanzmann's Thrombasthenia: A Report of Two Adult Patients.

    Rehman JU, Hussain F, Mahmood SK, et al.

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2022; (32(12)):1626-1628 doi:10.29271/jcpsp.2022.12.1626.

    PMID: 36474390
  9. 9

    The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention.

    Poon MC, d'Oiron R, Zotz RB, et al.

    Haematologica 2015; (100(8)):1038-44 doi:10.3324/haematol.2014.121384.

    PMID: 26001792
  10. 10

    The International Prospective Glanzmann Thrombasthenia Registry: Pediatric Treatment and Outcomes.

    Zotz RB, Poon MC, Di Minno G, et al.

    TH open : companion journal to thrombosis and haemostasis 2019; (3(3)):e286-e294 doi:10.1055/s-0039-1696657.

    PMID: 31523745
  11. 11

    Two homozygous missense mutations in ITGB3 gene as a cause of Glanzmann Thrombasthenia in four consanguineous Pakistani pedigrees.

    Ali T, Gul S, Amar A, et al.

    International journal of laboratory hematology 2020; (42(5)):628-635 doi:10.1111/ijlh.13266.

    PMID: 32558238
  12. 12

    Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies.

    Mathews N, Rivard GE, Bonnefoy A

    Journal of blood medicine 2021; (12()):449-463 doi:10.2147/JBM.S271744.

    PMID: 34149292
  13. 13

    Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options.

    Solh T, Botsford A, Solh M

    Journal of blood medicine 2015; (6()):219-27 doi:10.2147/JBM.S71319.

    PMID: 26185478
  14. 14

    Novel mutations in Thai patients with glanzmann thrombasthenia.

    Ittiwut R, Suchartlikitwong P, Kittikalayawong Y, et al.

    European journal of haematology 2017; (99(6)):520-524 doi:10.1111/ejh.12965.

    PMID: 28888044
  15. 15

    Emergency management of patients with Glanzmann thrombasthenia: consensus recommendations from the French reference center for inherited platelet disorders.

    Fiore M, Giraudet JS, Alessi MC, et al.

    Orphanet journal of rare diseases 2023; (18(1)):171 doi:10.1186/s13023-023-02787-2.

    PMID: 37386449
  16. 16

    New Insights Into the Treatment of Glanzmann Thrombasthenia.

    Poon MC, Di Minno G, d'Oiron R, Zotz R

    Transfusion medicine reviews 2016; (30(2)):92-9.

    PMID: 26968829
  17. 17

    Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.

    Di Minno G

    Blood reviews 2015; (29 Suppl 1()):S26-33.

    PMID: 26073366
  18. 18

    Outcomes of recombinant activated factor VIIa (NovoSeven) therapy in glanzmann thrombasthenia: two case reports.

    Almatar E, Alsharidah S, Hashem OA

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2025; (36(6)):293-295 doi:10.1097/MBC.0000000000001380.

    PMID: 40673721
  19. 19

    Immune gene polymorphisms associated with poor response to platelet transfusion and recombinant factor VII administration in Glanzmann thrombasthenia.

    Naderi M, Mirzaei I, Seidizadeh O, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2024; (30(3)):752-764 doi:10.1111/hae.14971.

    PMID: 38439143
  20. 20

    Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review.

    Saultier P, Grino M, Falaise C, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2025; (31(1)):7-15 doi:10.1111/hae.15130.

    PMID: 39604156
  21. 21

    Two case reports of Glanzmann thrombasthenia with intracranial hemorrhage and a review of the literature.

    Almesedin GS, Alshmaily HO, Alshammari KA, Albalawi RS

    Surgical neurology international 2023; (14()):448 doi:10.25259/SNI_680_2023.

    PMID: 38213436
  22. 22

    Lessons Learned: Deformity Correction and Tibiotalocalcaneal Arthrodesis in a Patient With Glanzmann Thrombasthenia: A Case Report.

    Lam K, Janney C, Panchbhavi V

    JBJS case connector 2020; (10(1)):e0277 doi:10.2106/JBJS.CC.19.00277.

    PMID: 32044772
  23. 23

    Management of Severe Menorrhagia in an Adolescent with Glanzmann Thrombasthenia: A Case Report and Treatment Approach.

    Tiwari SK, Sonowal R, Bhowmick R, Joshi P

    Journal of pediatric and adolescent gynecology 2026; (39(2)):253-257 doi:10.1016/j.jpag.2025.11.008.

    PMID: 41265828
  24. 24

    Iron deficiency anemia and bleeding management in pediatric patients with Bernard-Soulier syndrome and Glanzmann Thrombasthenia: A single-institution analysis.

    Lee A, Maier CL, Batsuli G

    Haemophilia : the official journal of the World Federation of Hemophilia 2022; (28(4)):633-641 doi:10.1111/hae.14559.

    PMID: 35412688
  25. 25

    Ferric carboxymaltose for sub-acute and chronic iron deficiency anemia in inherited platelet function defects.

    Scaramellini N, Capecchi M, Artoni A, et al.

    Internal and emergency medicine 2021; (16(2)):505-507 doi:10.1007/s11739-020-02478-x.

    PMID: 32845453
  26. 26

    Obstetric and Gynaecological Challenges and Outcomes in Women and Girls With Glanzmann's Thrombasthenia.

    Obeng-Tuudah D, Tarawah A, Ozkan M, Abdul-Kadir R

    Haemophilia : the official journal of the World Federation of Hemophilia 2025; (31(3)):509-518 doi:10.1111/hae.70030.

    PMID: 40123272

This page provides information on treatment options for Glanzmann Thrombasthenia for educational purposes. Always consult a hematologist to discuss the safest management plan for your specific bleeding risks.

Get notified when new evidence is published on Glanzmann Thrombasthenia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.